'Sniffing' urine to detect prostate cancer could prevent unnecessary biopsies
SAN FRANCISCO, April 3, 2017 — On the list of dreaded medical tests, a prostate biopsy probably ranks fairly high. The common procedure requires sticking a needle into the prostate gland to remove tissue for assessment. Thousands of men who undergo the uncomfortable procedure, prompted by a positive PSA (prostate-specific antigen) test, ultimately don't require cancer treatment. Today, scientists report progress toward minimizing unnecessary biopsies: They have identified the molecules likely responsible for the scent of prostate cancer, which could be detected by chemically "sniffing" urine.
The researchers will present their results today at the 253rd National Meeting & Exposition of the American Chemical Society (ACS). ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features more than 14,000 presentations on a wide range of science topics.
"The idea for this project started with a study published in 2014 showing that trained canines could detect prostate cancer with greater than 97 percent accuracy," says Mangilal Agarwal, Ph.D., the project's principal investigator. His team had already been working on a sensor to sniff hypoglycemia on a person's breath as dogs have also been shown to do. When the prostate cancer study appeared in the Journal of Urology, Agarwal's lab set out to determine what molecules the dogs might be sensing.
"If dogs can smell prostate cancer, we should be able to, too," says Amanda Siegel, Ph.D., who is presenting the work at the meeting. Both Agarwal and Siegel are at the Integrated Nanosystems Development Institute of Indiana University-Purdue University Indianapolis (IUPUI) and the Richard L. Roudebush VA Medical Center.
Prostate cancer is the third most common type of cancer in the United States. In 2016, more than 180,000 new cases were diagnosed, according to the U.S. National Institutes of Health's National Cancer Institute. Early detection has been critical to saving the lives of many men with prostate cancer. But diagnosing the disease can be fraught with challenges.
The screening test that doctors use now to determine whether to perform a biopsy assesses PSA levels in a blood sample. The prostate gland normally produces this protein in small amounts. Increased levels, however, can indicate many different conditions besides cancer, including prostate infection. As a result, the test is widely recognized as flawed and often leads to unnecessary biopsies.
"Currently, about 60 percent of men who get a biopsy to test for prostate cancer don't need to get one," Siegel says. "We hope our research will help doctors and patients make better-informed decisions about whether to have a biopsy, and to avoid unwarranted procedures."
To determine which molecules wafting from urine could indicate prostate cancer in a patient, the IUPUI and VA team collected urine samples from 100 men undergoing prostate biopsies. To avoid issues that similar studies have had with sample degradation, Agarwal's team developed a pre-processing step — adding sodium chloride and neutralizing the pH — to ensure the samples would remain intact during the analysis. Then, they used gas chromatography-mass spectrometry to identify the volatile organic compounds floating in the "headspace" above the urine samples. With this method, the researchers pinpointed a small set of molecules that showed up in 90 percent of the samples from patients with prostate cancer but not in samples from those who did not have the disease.
Next, the team plans to conduct large-scale tests at multiple health centers to validate their findings. They have also submitted a proposal for funding to confirm the molecular signature they identified by collaborating with a local dog trainer and comparing their technique's results to those obtained with a canine nose. Depending on the outcome of these projects, Siegel and Agarwal say their test could become available to patients and doctors within the next few years. In the short-term, urine samples would have to be sent to a lab for analysis, but the researchers say their ultimate goal is to design a sensor that can yield results in a doctor's office.
A press conference on this topic will be held Monday, April 3, at 1 p.m. Pacific time in the Moscone Center. Reporters may check-in at the press center, South Building, Foyer, or watch live on YouTube http://bit.ly/ACSLive_SanFrancisco. To ask questions online, sign in with a Google account.
The researchers acknowledge support and funding from the Richard L. Roudebush VA Medical Center.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With nearly 157,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact [email protected]
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Follow us: Twitter | Facebook
Investigation of biomarkers to screen for prostate cancer in urine using gas chromatography/mass spectrometry
Currently, the prostate specific antigen (PSA) test is used to identify patients to biopsy for prostate cancer, but it is so nonspecific that about two-thirds of people recommended for biopsy by PSA levels have either no sign of prostate cancer or an indolent form for which no treatment is required. Trained canines, however, can identify prostate cancer with 97% accuracy from sniffing urine headspace. This project collected urine samples from patients undergoing biopsies for prostate cancer, analyzed the headspace by solid phase microextraction coupled with gas chromatography-mass spectrometry, and identified candidate volatile organic compound biomarkers. The specific identification of headspace biomarkers for prostate cancer from urine can provide the basis for a noninvasive cancer screening tool.
415-978-3605 (San Francisco Press Center, April 2-5)
Katie Cottingham, Ph.D.